288 related articles for article (PubMed ID: 16322991)
1. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
2. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
[TBL] [Abstract][Full Text] [Related]
6. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
Sweeney CJ; Takimoto CH; Latz JE; Baker SD; Murry DJ; Krull JH; Fife K; Battiato L; Cleverly A; Chaudhary AK; Chaudhuri T; Sandler A; Mita AC; Rowinsky EK
Clin Cancer Res; 2006 Jan; 12(2):536-42. PubMed ID: 16428497
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.
Ouellet D; Periclou AP; Johnson RD; Woodworth JR; Lalonde RL
Cancer Chemother Pharmacol; 2000; 46(3):227-34. PubMed ID: 11021740
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients.
Latz JE; Schneck KL; Nakagawa K; Miller MA; Takimoto CH
Clin Cancer Res; 2009 Jan; 15(1):346-54. PubMed ID: 19118064
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
[TBL] [Abstract][Full Text] [Related]
20. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]